A patient-derived organoid model identifies TP53-dependent gemcitabine sensitivity in spinal chordoma
Panpan Hu, Shengxin Zeng, Juncai Lei, Hua Zhou, Ben Wang, Zhongjun Liu, Xiaoguang Liu, Feng Wei · 2026
Read A patient-derived organoid model identifies TP53-dependent gemcitabine sensitivity in spinal chordoma by Panpan Hu, Shengxin Zeng, Juncai Lei, Hua Zhou, Ben Wang, Zhongjun Liu, Xiaoguang Liu, Feng Wei (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13272820.txt.
Description
Panpan Hu and seven co-authors grow mini-tumors from patients' spinal chordomas to test drug response, in a study from twenty twenty-six. Chordoma is a rare bone cancer with few working drug options, and standard chemotherapy barely helps. Lab-grown organoids can preserve a tumor's traits and screen drugs, but linking pathways to response in this cancer was untested.
Organoids grown from surgical samples matched their source tumors and stayed stable over six passages. Screening a panel of clinical drugs found one, gemcitabine, hit hardest. Silencing the TP53 gene then blunted the drug's killing effect and let cells keep dividing. The authors conclude the drug's power here depends on TP53, a clue for choosing patients.
Catalog record
| CREATOR | Panpan Hu, Shengxin Zeng, Juncai Lei, Hua Zhou, Ben Wang, Zhongjun Liu, Xiaoguang Liu, Feng Wei |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |